Pharmaceuticals, Biotechnology and Life Sciences
PledPharma will present its “first in class” drug candidate PledOx phase III program at the Gastrointestinal (GI) Cancers Symposium, taking place in San Francisco today and tomorrow.
Actelion Pharmaceuticals will need to provide more data to evaluate the use of Opsumit in the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension.
Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ALK genomic tumour aberrations.
Innovent Biologics has started testing on patients its Tyvyt, fully human anti-PD-1 therapeutic monoclonal antibody, with generic name sintilimab injection, in combination with capecitabine and oxaliplatin, patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).
Aquinnah Pharmaceuticals got $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases.
Geron Corporation has included the first of several key leadership positions in rebuilding its in-house development team to boost a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.
Neurocrine Biosciences, published a new analysis of Ingrezza (valbenazine) capsules, in the Journal of Affective Disorders, pointing out improvement in tardive dyskinesia (TD) symptoms in patients with primary mood disorders, with no clinically meaningful changes to psychiatric stability.
ADC Therapeutics, oncology drug specialist started the Phase I clinical testing ADCT-601 on patients with selected solid tumors that are locally advanced or metastatic.
Innovent Biologics has dosed the first patient in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.
Array BioPharma’s updated results from the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI (encorafenib), a BRAF inhibitor, MEKTOVI (binimetinib), a MEK inhibitor and ERBITUX (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), was generally well-tolerated with no unexpected toxicities.